Sanger Institute, St Jude Data-Sharing Agreement
News Sep 20, 2016
The Wellcome Trust Sanger Institute is combining the power of COSMIC, its large-scale cancer genetics database, with ProteinPaint data mining and visualization system at St. Jude Children’s Research Hospital in Memphis TN, to support the discovery and understanding of genetic mutations in paediatric cancers.
The agreement will provide regular updates and exchanges of cancer mutation data between both institutions to ensure the best support for research in all areas of childhood cancer, and will be freely available to researchers in all areas of science.
St. Jude Children’s Research Hospital is the leading institute in the US for research on understanding the genetic basis of paediatric forms of blood, brain and bone cancers. To characterise the genetic variants responsible for driving cancer formation in children, the hospital sequences the DNA from hundreds of childhood tumours. Their new system to explore this data, ProteinPaint, has been carefully designed to provide simple and easy ways to visualise and understand such large quantities of information.
The challenge is to identify which genetic variations are playing an active role in driving cancer development and which are there by chance - simply passengers along for the ride. It is only by comparing the childhood tumour genomes with many other tumour genomes that the “cancer drivers” can be separated from the “passengers”.
To enable such large-scale comparison, the Sanger Institute developed COSMIC - the Catalogue of Somatic Mutations In Cancer - an expert-curated database describing the wide variety of genetic variations associated with all forms of human cancer. COSMIC has been developed and maintained for more than 12 years and contains data on more than 4 million mutations.
"It's very exciting to be working with St. Jude to help characterise the causes of childhood cancer. Many of our users are supporting diagnostic and pharmaceutical discovery and in this way we hope to support future improvements for these young patients." – Dr Simon Forbes, Head of COSMIC at the Wellcome Trust Sanger Institute
“We want this to be the definitive resource for genomic information for the pediatric cancer community. This collaboration will allow us to share data across two institutions to better understand, using our combined knowledge, what causes cancer.” – Dr Jinghui Zhang, chair of St. Jude’s department of computational biology
CRISPR Screening Reveals Sickle Cell Disease TargetNews
A key signaling protein, known as heme-regulated inhibitor (HRI), has been identified as a potential therapeutic target for the development of drugs to treat sickle cell disease, using a CRISPR screening approach.READ MORE
DNA Methylation Related to Liver Disease in Obese PatientsNews
DNA methylation implicated in initiation of liver fibrosis in non-alcoholic fatty liver diseaseREAD MORE
UCL Technology Fund Investment MeiraGTx Raises $75 Million in IPONews
MeiraGTx Holdings plc raised $75 million of gross proceeds upon close of the company’s initial public offering (IPO).READ MORE
International Conference on Neurooncology and Neurosurgery
Sep 17 - Sep 18, 2018